For adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL), the steepest barriers to high-quality care ...

The global acute lymphocytic leukemia (ALL) market is set for substantial growth from 2025 to 2035, fueled by advances in chemotherapy, targeted therapies, and immunotherapy. Particularly affecting ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...

Key Takeaways Leukemia is more threatening to Black patients than white patientsBlack patients tend to be diagnosed years ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

The report charts major advances in precision oncology and immunotherapy but also reveals stagnant survival for several ...

A pioneering genetic treatment is saving lives where chemotherapy failed, offering new hope for children and adults with ...

A chemotherapy-free-based regimen of the TKI ponatinib combined with targeted immunotherapy showed significant benefits in ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...